{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:10:04Z","timestamp":1767838204332,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"S\u00f8rlandet Sykehus HF"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individuals with opioid use disorder (OUD) often have concurrent use of non-opioid substances. When patients enter opioid maintenance treatment (OMT), less is known about outcomes regarding the use of other types of drugs. Here we aimed to investigate changes in substance use among patients entering outpatient OMT, from treatment initiation to 1-year follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used data from the prospective Norwegian Cohort of Patient in OMT and Other Drug Treatment Study (NorComt). Among 283 patients who entered OMT at participating facilities across Norway, 179 were assessed at follow-up. Of these patients, 131 were in a non-controlled environment, and were included in the present analysis. The main outcome was change in substance use. Logistic regression analysis was applied to identify factors associated with abstinence from all substances (other than agonist medication) at follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Along with opioid use, most patients reported polysubstance use prior to entering treatment. No significant differences were found in baseline characteristics between the included and non-included groups when examining attrition. At the 1-year follow-up, reduced substance use was reported. While in treatment, around two-thirds of patients continued using other drugs to varying degrees. At follow-up, about one-third of patients reported abstinence from all drugs, apart from the agonist medication. Factors related to abstinence included a goal of abstinence at baseline (OR\u2009=\u20095.26; 95% CI 1.14\u201319.55; <jats:italic>p<\/jats:italic>\u2009=\u20090.013) and increasing age (OR\u2009=\u20091.05; 95% CI 1.00\u20131.09; <jats:italic>p<\/jats:italic>\u2009=\u20090.034).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of patients entering OMT used other substances in addition to opioids. About one-third of patients reported abstinence at the 1-year follow up. Although the majority of patients continued co-use of other drugs while in treatment, for most substances, less than 10% reported daily use at follow-up, with the exception of cannabis which was used daily\/almost daily by about 2 in 10. Higher age and treatment goal at the start of OMT were important factors related to reducing concomitant substance use during treatment. These findings suggest that many patients entering OMT are in need of treatment and support related to the use of other substances, to further improve prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov no. NCT05182918. Registered 10\/01\/2022 (the study was retrospectively registered).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01005-x","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:02:22Z","timestamp":1716595342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up"],"prefix":"10.1186","volume":"21","author":[{"given":"Endre Dahlen","family":"Bj\u00f8rnestad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-K\u00e5re","family":"Vederhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL. Opioid use disorder. Nat Rev Dis Primers. 2020;6:3.","journal-title":"Nat Rev Dis Primers"},{"key":"1005_CR2","doi-asserted-by":"crossref","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016.","DOI":"10.1002\/14651858.CD011117.pub2"},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication treatment of opioid Use Disorder. Biol Psychiatry. 2020;87:82\u20138.","journal-title":"Biol Psychiatry"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394:1560\u201379.","journal-title":"Lancet"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"1005_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94:151\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, Chen A, Tran LT, Bharat C, Padmanathan P, et al. Association of Opioid Agonist Treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78:979\u201393.","journal-title":"JAMA Psychiatry"},{"key":"1005_CR8","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/bmjopen-2011-000130","volume":"1","author":"I Skeie","year":"2011","unstructured":"Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H. Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study. BMJ Open. 2011;1:e000130.","journal-title":"BMJ Open"},{"key":"1005_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12888-021-03518-2","volume":"21","author":"I Skj\u00e6rv\u00f8","year":"2021","unstructured":"Skj\u00e6rv\u00f8 I, Clausen T, Skurtveit S, Bukten A. Desistance from crime following substance use treatment: the role of treatment retention, social network and self-control. BMC Psychiatry. 2021;21:563.","journal-title":"BMC Psychiatry"},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"108005","DOI":"10.1016\/j.drugalcdep.2020.108005","volume":"212","author":"H Dong","year":"2020","unstructured":"Dong H, Hayashi K, Milloy MJ, DeBeck K, Singer J, Wong H, Wood E, Kerr T. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005.","journal-title":"Drug Alcohol Depend"},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/add.15116","volume":"116","author":"LA Lin","year":"2021","unstructured":"Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116:96\u2013104.","journal-title":"Addiction"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"106752","DOI":"10.1016\/j.addbeh.2020.106752","volume":"114","author":"JJ Mahoney","year":"2021","unstructured":"Mahoney JJ 3rd, Winstanley EL, Lander LR, Berry JH, Marshalek PJ, Haut MW, Marton JL, Kimble WD, Armistead M, Wen S, et al. High prevalence of co-occurring substance use in individuals with opioid use disorder. Addict Behav. 2021;114:106752.","journal-title":"Addict Behav"},{"key":"1005_CR13","first-page":"20","volume":"16","author":"CF Aas","year":"2021","unstructured":"Aas CF, Vold JH, Gjestad R, Skurtveit S, Lim AG, Gjerde KV, L\u00f8berg E-M, Johansson KA, Fadnes LT, Buljovcic VB, et al. Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. Subst Abuse: Treat Prev Policy. 2021;16:20.","journal-title":"Subst Abuse: Treat Prev Policy"},{"key":"1005_CR14","doi-asserted-by":"publisher","first-page":"106752","DOI":"10.1016\/j.addbeh.2020.106752","volume":"114","author":"JJ Mahoney","year":"2021","unstructured":"Mahoney JJ, Winstanley EL, Lander LR, Berry JH, Marshalek PJ, Haut MW, Marton JL, Kimble WD, Armistead M, Wen S, et al. High prevalence of co-occurring substance use in individuals with opioid use disorder. Addict Behav. 2021;114:106752.","journal-title":"Addict Behav"},{"key":"1005_CR15","volume-title":"Polydrug use: patterns and responses","author":"EMCDDA (European Monitoring Centre for Drugs and Drug Addiction)","year":"2009","unstructured":"EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Polydrug use: patterns and responses. Luxembourg: Publications Office of the European Union: European Monitoring Centre for Drugs and Drug Addiction.; 2009."},{"key":"1005_CR16","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.jsat.2021.108329","volume":"126","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Williams AR, Saloner B, Cerd\u00e1 M. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021;126:108329.","journal-title":"J Subst Abuse Treat"},{"key":"1005_CR17","doi-asserted-by":"publisher","first-page":"e202361","DOI":"10.1001\/jamanetworkopen.2020.2361","volume":"3","author":"ME Tori","year":"2020","unstructured":"Tori ME, Larochelle MR, Naimi TS. Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999\u20132017. JAMA Netw Open. 2020;3:e202361\u2013202361.","journal-title":"JAMA Netw Open"},{"key":"1005_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/epirev\/mxaa005","volume":"42","author":"CT Blondino","year":"2020","unstructured":"Blondino CT, Gormley MA, Taylor DDH, Lowery E, Clifford JS, Burkart B, Graves WC, Lu J, Prom-Wormley EC. The influence of Co-occurring Substance Use on the effectiveness of Opiate Treatment Programs according to intervention type. Epidemiol Rev. 2020;42:57\u201378.","journal-title":"Epidemiol Rev"},{"key":"1005_CR19","first-page":"80","volume":"34","author":"Z Gaulen","year":"2017","unstructured":"Gaulen Z, Alpers SE, Carlsen SL, Nesvag S. Health and social issues among older patients in opioid maintenance treatment in Norway. Nordisk Alkohol Nark. 2017;34:80\u201390.","journal-title":"Nordisk Alkohol Nark"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.addbeh.2010.12.012","volume":"36","author":"D Rosen","year":"2011","unstructured":"Rosen D, Hunsaker A, Albert SM, Cornelius JR, Reynolds CF 3. Characteristics and consequences of heroin use among older adults in the United States: a review of the literature, treatment implications, and recommendations for further research. Addict Behav. 2011;36:279\u201385.","journal-title":"Addict Behav"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13011-020-00311-4","volume":"15","author":"D Medved","year":"2020","unstructured":"Medved D, Clausen T, Bukten A, Bj\u00f8rnestad R, Muller AE. Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients. Subst Abuse Treat Prev Policy. 2020;15:87.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drugalcdep.2014.12.019","volume":"147","author":"S Larney","year":"2015","unstructured":"Larney S, Bohnert AS, Ganoczy D, Ilgen MA, Hickman M, Blow FC, Degenhardt L. Mortality among older adults with opioid use disorders in the veteran\u2019s Health Administration, 2000\u20132011. Drug Alcohol Depend. 2015;147:32\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ps.56.8.927","volume":"56","author":"A MD D Charney","year":"2005","unstructured":"Dara A, Charney MD, Palacios-Boix J,, MD, Negrete JC,, MD, Dobkin PL, Ph.D.and, Gill KJ. Association between Concurrent Depression and anxiety and six-Month Outcome of Addiction Treatment. Psychiatr Serv. 2005;56:927\u201333.","journal-title":"Psychiatr Serv"},{"key":"1005_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12888-016-0881-y","volume":"16","author":"C Tjagvad","year":"2016","unstructured":"Tjagvad C, Clausen T, Handal M, Skurtveit S. Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000\u20132010. BMC Psychiatry. 2016;16:168.","journal-title":"BMC Psychiatry"},{"key":"1005_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12913-020-05195-5","volume":"20","author":"JH Vold","year":"2020","unstructured":"Vold JH, Skurtveit S, Aas C, Chalabianloo F, Kloster PS, Johansson KA, Fadnes LT. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC Health Serv Res. 2020;20:352.","journal-title":"BMC Health Serv Res"},{"key":"1005_CR26","unstructured":"EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Perspectives on drugs: The misuse of benzodiazepines among high-risk opioid users in Europe. 2018."},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"JD Jones","year":"2012","unstructured":"Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8\u201318.","journal-title":"Drug Alcohol Depend"},{"key":"1005_CR28","volume-title":"D\u00f8delighet Ved forskrivning av benzodiazepiner til personer i legemiddelassistert rehabilitering (LAR): en systematisk oversikt. [Benzodiazepine prescription and mortality among persons in opioid maintenance treatment (OMT): a systematic review]","author":"CH Hestevik","year":"2021","unstructured":"Hestevik CH, Evensen LH. D\u00f8delighet Ved forskrivning av benzodiazepiner til personer i legemiddelassistert rehabilitering (LAR): en systematisk oversikt. [Benzodiazepine prescription and mortality among persons in opioid maintenance treatment (OMT): a systematic review]. Oslo: Folkehelseinstituttet; 2021."},{"key":"1005_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/add.14289","volume":"114","author":"BD Kiluk","year":"2019","unstructured":"Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD. What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? Addiction. 2019;114:9\u201315.","journal-title":"Addiction"},{"key":"1005_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00228-010-0793-6","volume":"66","author":"P Lobmaier","year":"2010","unstructured":"Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction\u2013a clinical perspective. Eur J Clin Pharmacol. 2010;66:537\u201345.","journal-title":"Eur J Clin Pharmacol"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/02791072.2014.901587","volume":"46","author":"WL White","year":"2014","unstructured":"White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to Treatment Retention. J Psychoact Drugs. 2014;46:114\u201322.","journal-title":"J Psychoact Drugs"},{"key":"1005_CR32","first-page":"117822181984499","volume":"13","author":"H Pettersen","year":"2019","unstructured":"Pettersen H, Landheim A, Skeie I, Biong S, Brodahl M, Benson V, Davidson L. Helpful ingredients in the treatment of Long-Term Substance Use disorders: a collaborative narrative study. Subst Abuse. 2019;13:1178221819844996.","journal-title":"Subst Abuse"},{"key":"1005_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.drugalcdep.2017.09.006","volume":"180","author":"AE Muller","year":"2017","unstructured":"Muller AE, Skurtveit S, Clausen T. Building abstinent networks is an important resource in improving quality of life. Drug Alcohol Depend. 2017;180:431\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"1005_CR34","volume-title":"Nasjonal retningslinje for legemiddelassistert rehabilitering ved opioidavhengighet (national guideline for medication assisted treatment for opioid dependence)","author":"The Norwegian Directorate of Health (Helsedirektoratet)","year":"2010","unstructured":"The Norwegian Directorate of Health (Helsedirektoratet). Nasjonal retningslinje for legemiddelassistert rehabilitering ved opioidavhengighet (national guideline for medication assisted treatment for opioid dependence). Oslo: The Norwegian Directorate of Health (Helsedirektoratet); 2010."},{"key":"1005_CR35","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1080\/10826084.2017.1413114","volume":"53","author":"KF Abel","year":"2018","unstructured":"Abel KF, Skj\u00e6rv\u00f8 I, Ravndal E, Clausen T, Bramness JG. Perceived self-control is related to Mental Distress in patients entering Substance Use Disorder Treatment. Subst Use Misuse. 2018;53:1454\u201362.","journal-title":"Subst Use Misuse"},{"key":"1005_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12955-016-0439-1","volume":"14","author":"AE Muller","year":"2016","unstructured":"Muller AE, Skurtveit S, Clausen T. Many correlates of poor quality of life among substance users entering treatment are not addiction-specific. Health Qual Life Outcomes. 2016;14:39.","journal-title":"Health Qual Life Outcomes"},{"key":"1005_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J. The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90:607\u201314.","journal-title":"Addiction"},{"key":"1005_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addbeh.2015.05.001","volume":"48","author":"JB Andreas","year":"2015","unstructured":"Andreas JB, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71\u20138.","journal-title":"Addict Behav"},{"key":"1005_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bs.3830190102","volume":"19","author":"LR Derogatis","year":"1974","unstructured":"Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1\u201315.","journal-title":"Behav Sci"},{"key":"1005_CR40","volume-title":"Gjennom 10 \u00e5r - En oppf\u00f8lgingsstudie av narkotikabrukere i behandling (through 10 years: a follow-up study of patients in treatment]","author":"G Lauritzen","year":"2012","unstructured":"Lauritzen G, Ravndal E, Larsson J. Gjennom 10 \u00e5r - En oppf\u00f8lgingsstudie av narkotikabrukere i behandling (through 10 years: a follow-up study of patients in treatment]. Oslo: Statens institutt for rusmiddelforskning; 2012."},{"key":"1005_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/10550887.2013.795468","volume":"32","author":"S Trocchio","year":"2013","unstructured":"Trocchio S, Chassler D, Storbj\u00f6rk J, Delucchi K, Witbrodt J, Lundgren L. The Association between Self-Reported Mental Health Status and Alcohol and drug abstinence 5 years Post-assessment for an addiction disorder in U.S. and Swedish samples. J Addict Dis. 2013;32:180\u201393.","journal-title":"J Addict Dis"},{"key":"1005_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14659890410001697415","volume":"9","author":"G Lauritzen","year":"2009","unstructured":"Lauritzen G, Ravndal E. Introduction of the EuropASI in Norway: clinical and research experiences from a cost-effectiveness study. J Subst Use. 2009;9:141\u20136.","journal-title":"J Subst Use"},{"key":"1005_CR43","volume-title":"Multivariate Data Analysis","author":"JF Hair","year":"2019","unstructured":"Hair JF, Babin BJ, Black WC, Anderson RE. Multivariate Data Analysis. 8th ed. United Kingdom: Cengage; 2019.","edition":"8"},{"key":"1005_CR44","volume-title":"Practical statistics for medical research. Douglas G. Altman, London, 1991. No. Of pages: 611","author":"DG Altman","year":"1991","unstructured":"Altman DG. Practical statistics for medical research. Douglas G. Altman, London, 1991. No. Of pages: 611. London: Chapman and Hall\/CRC; 1991."},{"key":"1005_CR45","volume-title":"IBM SPSS statistics for Windows, Version 28","author":"IBM Corp","year":"2021","unstructured":"IBM Corp. IBM SPSS statistics for Windows, Version 28. Armonk, NY: IBM Corp; 2021."},{"key":"1005_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13011-021-00403-9","volume":"16","author":"JH Vold","year":"2021","unstructured":"Vold JH, Chalabianloo F, Aas CF, L\u00f8berg EM, Johansson KA, Fadnes LT. Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. Subst Abuse Treat Prev Policy. 2021;16:67.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1005_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/SAR.S221618","volume":"11","author":"SL Carlsen","year":"2020","unstructured":"Carlsen SL, Lunde LH, Torsheim T. Opioid and Polydrug Use among patients in opioid maintenance treatment. Subst Abuse Rehabil. 2020;11:9\u201318.","journal-title":"Subst Abuse Rehabil"},{"key":"1005_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207\u201325.","journal-title":"J Addict Dis"},{"key":"1005_CR49","unstructured":"Bech AB, Bukten A, Lobmaier P, Skeie I, Lillevold PH, Clausen T. Statusrapport 2021: Siste \u00e5r med gamle LAR-retningslinjer. 2022."},{"key":"1005_CR50","unstructured":"The Norwegian Directorate of Health (Helsedirektoratet): Nasjonal faglig retningslinje for legemiddelassistert rehabilitering (LAR) ved opioidavhengighet (National guideline for medication assisted treatment for opioid dependence). Oslo: Helsedirektoratet; 2022."},{"key":"1005_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2215-0366(17)30073-1","volume":"4","author":"WD Hall","year":"2017","unstructured":"Hall WD, Strang J. Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. Lancet Psychiatry. 2017;4:265\u20136.","journal-title":"Lancet Psychiatry"},{"key":"1005_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/alcalc\/agq005","volume":"45","author":"SJ Adamson","year":"2010","unstructured":"Adamson SJ, Heather N, Morton V, Raistrick D. Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol. 2010;45:136\u201342.","journal-title":"Alcohol Alcohol"},{"key":"1005_CR53","doi-asserted-by":"publisher","first-page":"438","DOI":"10.15288\/jsad.2014.75.438","volume":"75","author":"KS DeMartini","year":"2014","unstructured":"DeMartini KS, Devine EG, DiClemente CC, Martin DJ, Ray LA, O\u2019Malley SS. Predictors of pretreatment commitment to abstinence: results from the COMBINE study. J Stud Alcohol Drugs. 2014;75:438\u201346.","journal-title":"J Stud Alcohol Drugs"},{"key":"1005_CR54","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0306-4603(02)00219-8","volume":"28","author":"R Secades-Villa","year":"2003","unstructured":"Secades-Villa R, Fern\u00e1ndez-Hermida JR. The validity of self-reports in a follow-up study with drug addicts. Addict Behav. 2003;28:1175\u201382.","journal-title":"Addict Behav"},{"key":"1005_CR55","first-page":"200","volume":"167","author":"ED Wish","year":"1997","unstructured":"Wish ED, Hoffman JA, Nemes S. The validity of self-reports of drug use at treatment admission and at followup: comparisons with urinalysis and hair assays. NIDA Res Monogr. 1997;167:200\u201326.","journal-title":"NIDA Res Monogr"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01005-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T01:03:59Z","timestamp":1716599039000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01005-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01005-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by The Regional Committee for Research Ethics in Norway (REK 2012\/1131). All methods were used in accordance with relevant guidelines and regulations. Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}